Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
January 08, 2023 19:00 ET
|
Esperion Therapeutics, Inc.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...